Focus on Patients
-
2 Key Ways To Improve Patient Recruitment Of Minorities In Clinical Trials – A Participant’s Perspective
6/1/2021
John A. Reaves was compelled to participate in clinical trials for a COVID-19 vaccine. In this article, he discusses his experience and provides two recommendations, including potential strategies for accomplishing them, for how the industry can improve recruitment of minorities for clinical trials.
-
Best Practices For Designing And Running Clinical Trials For Patients With Rare Diseases
5/25/2021
As an industry, we are constantly searching for ways to improve the drug development process – particularly in the rare disease space. One way to improve on running your rare disease clinical trial is to foster collaborative partnerships with patient advocacy organizations and to stay connected to patients throughout the trial. Here's how to do that.
-
Incorporating The Voices Of Parents And Children In Pediatric Clinical Trials
3/9/2021
Pediatric trials are far more complex than simply evaluating a therapy in the context of a child’s disease or illness. They are a family affair that must accommodate the diverse needs of parents and other family members caring for those children. This article discusses recent survey findings from the Center for Information and Study on Clinical Research Participation.
-
Best Practices For Implementing Decentralized Clinical Trials
1/12/2021
While the experience design related to the patient is paramount to the adoption of decentralized clinical trial technology, the interrelated experience and incentives for all stakeholders must be fully aligned to realize the full benefits of these platforms.
-
Lessons For Leaders: The Loud And Lasting Impact Of COVID-19 On The Future Of Clinical Research
12/15/2020
Last year, shortly before the pandemic, we predicted that clinical trials of the future would be more open, more human-centered, and more integrated in the healthcare ecosystem, providing guideposts for how industry will adapt along these three themes. COVID-19 has both accelerated these trends and highlighted new challenges for R&D leaders to address.
-
Janssen’s Patient-centric Approach To Psychiatric Disease Management
11/10/2020
Diseases as complex as those of the brain require an equally complex approach, centered on the unique needs, goals, and circumstances of the individual patients, as well as the loved ones who support them. Listening, empathizing, understanding — these basic human interactions will have a critical role in our ability to reach our goal and deliver transformational medical innovations.
-
Ensuring Patient-Friendly Clinical Trials For Complex Disorders — A Small Biopharma’s Playbook
10/22/2020
Rezolute, a small company working in the rare pediatric disease space, is developing a new therapeutic option specifically for patients with congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. Connecting and partnering with advocacy groups and physicians is paramount in the company's clinical trial execution.
-
4 Practical Ways To Improve The Patient Experience In Clinical Trials
10/13/2020
Stakeholders have recognized the need for patients and advocates to have a seat at the table and be the central focus in enterprise approaches, commercialization, and research and development. How can we gather as much data in as few studies as possible? And in doing this, how can we acknowledge the impact that taking part in a trial has on the patients we are working to help?
-
9 Factors For Driving Inclusivity & Patient Centricity In A Transformed Clinical Trials Landscape
9/15/2020
Patient-centricity, quality, and inclusion are not natural consequences of the shift to virtual clinical trials. To be intentional with the design, we must start with articulating and understanding the full contexts of patients’ lives, medical and beyond.
-
4 Best Practices That Kept A Biotech’s Clinical Trial Moving In The COVID-19 Era
8/12/2020
The timely enrollment and progression of clinical trials is critical for a pre-commercial biotech company, as delays can keep treatments from getting to patients and cost an organization significant money and reputation. When you throw in a worldwide pandemic, it’s a whole new ball game.